Jens Hoffmann, PhDCEO at EPO Berlin-Buch GmbH (EPO)Speaker
Profile
Dr Hoffmann is the CEO of EPO, a CRO that provides comprehensive services for preclinical oncology research. He has specialized in preclinical and translational research and is developing personalized models to support the selection of the most appropriate drug treatment for individual patients. From 1997 to 2009 he worked as group leader in Oncology Research at Schering and Bayer. Dr. Hoffmann is member of the German Cancer Foundation and the Board of the Experimental Cancer Research Division (AEK) and the AACR. He is member of the CONELIS expert network and of the board of CPO Cellular Phenomics and Oncology.